Noema Pharma raises CHF54 million in Series A financing round: the advisors

Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders, announced it has successfully concluded an oversubscribed Series A financing round, raising CHF54 million ($59 million USD) to fund further development of its promising clinical-stage pipeline. The round was co-led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and Polaris Partners, a healthcare and technology investment firm based in the United States. The global consortium of new international investors includes Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates.

The advisors

VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left) with Christian Wyss (Corporate), Nadia Tarolli (Tax), Vincent Reardon (Corporate) and Pauline Pfirter (Corporate).

Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors on the CHF 54m series A financing of Noema Pharma. The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital – pictured right), Robert von Rosen (Partner, Corporate/M&A and Venture Capital), Markus R. Frick (Partner, IP/IT) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).